Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2013

01.12.2013 | editorial

Antibody–drug conjugates (ADCs)—new targeted therapies

verfasst von: Dr. Georgios Papakonstantinou, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The promise of all targeted therapies is the specific induction of cytotoxicity in malignant cells without adversely affecting normal tissues. Antibody–drug conjugates (ADCs) consist of a monoclonal antibody chemically linked to an anticancer agent, and are a niche class of drugs that raise great expectations, particularly as oncology drugs. Brentuximab vedotin and trastuzumab emtansine, both recently US Food and Drug Administration approved, open a promising new area in the therapy of hematologic malignancies and solid tumors. Further improvement of bioengineering and development of preclinical and clinical data are the challenges for the next generation of ADCs.
Literatur
2.
Zurück zum Zitat Claro RA, Karen McGinnK, Kwitkowski V, et al. U.S. Food and drug administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18(21):5845–9.PubMedCrossRef Claro RA, Karen McGinnK, Kwitkowski V, et al. U.S. Food and drug administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18(21):5845–9.PubMedCrossRef
3.
Zurück zum Zitat Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.PubMedCrossRef Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.PubMedCrossRef
Metadaten
Titel
Antibody–drug conjugates (ADCs)—new targeted therapies
verfasst von
Dr. Georgios Papakonstantinou, MD, PhD
Publikationsdatum
01.12.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0116-6

Weitere Artikel der Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013 Zur Ausgabe